Theravance Biopharma (TBPH) Free Cash Flow (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Free Cash Flow data on file, last reported at $73.3 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 70.26% year-over-year to $73.3 million in Q1 2026; TTM through Mar 2026 was $268.8 million, a 732.5% increase from a year earlier, with the FY2025 full-year figure at $238.5 million, up 2109.77% from the prior year.
• Free Cash Flow for Q1 2026 stood at $73.3 million, up from -$6.1 million in the prior quarter.
• Over the last five years, Free Cash Flow for TBPH reached as high as $208.1 million in Q2 2025 and fell as low as -$26.3 million in Q1 2022.
• Historically, Free Cash Flow has averaged $15.7 million across 5 years, with a median of -$4.5 million in 2024.
• On a YoY basis, Free Cash Flow climbed as much as 4774.77% in 2025 and fell as far as 456.04% in 2025.
• Year by year, Free Cash Flow stood at $54.6 million in 2022, then sank by 102.8% to -$1.5 million in 2023, then rose by 28.67% to -$1.1 million in 2024, then sank by 456.04% to -$6.1 million in 2025, then soared by 1306.83% to $73.3 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $73.3 million in Q1 2026, -$6.1 million in Q4 2025, and -$6.5 million in Q3 2025.